



## PHARMACEUTICAL 2018









## PHARMACEUTICAL 2018



## Zynerba Pharmaceuticals Inc. Rank 75 of 342



The relative strengths and weaknesses of Zynerba Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zynerba Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 120% points. The greatest weakness of Zynerba Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 189%, being 143% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	68,228
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,443
Liabilities, Non-Current	0
Other Assets	662
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	662
Other Net Income	811
Other Revenues	0
Property and Equipment	165
Research and Development	22,806
Selling, General and Administrative Expense	10,017

Output Variable	Value in 1000 USD
Assets	69,054
Liabilities	8,105
Expenses	32,823
Revenues	0
Stockholders Equity	60,950
Net Income	-32,012
Comprehensive Net Income	-32,012
Economic Capital Ratio	189%